JBL Your CRDMO Partner in Science
JA
EN
  • About Us
    • Vision, Values & Promise
    • Company Overview
    • Leadership Team
    • Our Facilities
    • Contact Us
  • Services
    • Integrated Drug Discovery
      • Target Identification
      • Target Validation
      • HIT Identification
      • HIT to Lead
      • Lead Optimization
      • Candidate Selection
    • Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Analytical Chemistry
      • Computational Chemistry
      • Specialised Chemistry-COE
      • Oligonucleotide Offerings
    • Structural Biology
      • Custom Protein Production
      • SPR
      • Crystallography
      • SBDD
    • Assay Biology
      • In-Vitro Biology
      • Target Validation
      • Bio-Chemical Assay, D&S
      • Cell Based Assay, D&S
      • Mode of Action Studies
      • Biomarker Evaluation
    • DMPK
      • Physicochemical Properties
      • In-Vitro ADME
      • In-Vivo Pharmacokinetics
      • Drug Interactions
      • Metabolite Identification
      • Bioanalysis
      • Large Molecule Bioanalysis
    • Computational Chemistry (CADD)
      • Virtual Screening
      • LBDD
      • Insilico FBDD
      • Chemoinformatics
    • Pharmacology
      • Oncology Animal Models
      • Inflammation Animal Models
      • Pain and Neuroscience Animal Models
      • Diabetes & Metabolic Disorders Animal Models
    • Toxicology
      • GLP & Non GLP Studies
      • Acute Toxicity
      • Subchronic Toxicity
      • Genetic Toxicity
      • Safety Pharmacology
      • Toxicokinetics
    • CDMO
      • Process R&D Services
      • Analytical Development
      • Process Safety Studies
      • Polystate Capabilities
      • Technology Transfer
      • Early to Late Phase Supplies
      • GLP, Non-GMP and GMP Mfg.
    • API
      • API Capabilities
      • Product List
    • For more information reach us at: bd@jubilantbiosys.com
  • Target Approaches
    • Kinases
    • Non-Kinase Enzymes
    • GPCRs & Ion Channels
    • Transcription Factors
    • Immune Regulators
    • Target Protein Degradation
    • RNA Small Molecule Drugs
  • Our Commitment
    • EHS
    • Corporate Governance
    • Corporate Social Responsibility
    • Sustainability
    • Quality & IP
  • Resources
    • News
    • Press Releases
    • Events
    • Publications
    • Whitepapers
    • Brochures
    • Webinars
    • Customer Testimonials
  • Careers
    • Job Opportunities
    • Returning Indian Talent
    • Policies
    • Recruitment Fraud Advisory
    • Group Ombudsperson

A CRO that supports drug discovery ideas and passion – Jubilant Biosys

Posted on June 17, 2020December 5, 2024 by ddAdmin

BIO Impact Interview June 2020 with Dr Takeshi Yura

Posted in Publications

Post navigation

Previous: PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits
Next: An in vitro model of hepatic steatosis using lipid loaded induced pluripotent stem cell derived hepatocyte like cells

Get in touch

For Business Queries
bd@jubilantbiosys.com
For Career Related Queries
careers@jubilantbiosys.com

Services

  • Integrated Drug Discovery
  • Chemistry
  • Structural Biology
  • Assay Biology
  • DMPK
  • Computational Chemistry (CADD)
  • Pharmacology
  • Toxicology
  • CDMO

Our Locations

    R&D Centers
  • Noida, India
  • Greater Noida, India
  • Bengaluru, India
Manufacturing Plant
  • Nanjangud, India

Company

  • Facilities
  • Contact
  • Careers
  • News

© 2025 Jubilant Biosys Limited A Jubilant Pharmova Limited Company

  • Policies
  • Jubilant Group
  • Sitemap
  • Disclaimer
  • Payment

Request For Information

We appreciate all business enquiries, If you'd like our Business Development team to contact you, please complete this form.